Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 64 HER2-positive Breast Cancer 11 Carcinoma, Non-Small-Cell Lung 6 HER2 Positive Metastatic Breast Cancer 4 Breast Diseases 4 Brain Neoplasms 4 HER2 Positive Breast Cancer 3 Advanced Breast Cancer 3 Triple Negative Breast Neoplasms 2 Stomach Neoplasms 2 HER2-positive Metastatic Breast Cancer 2 Colorectal Neoplasms 2 Breast Cancer Invasive 2 Breast Cancer Female 2 Solid Tumor 1 Salivary Gland Neoplasms 1 Rare Tumour 1 Rare Tumor 1 Pathologic Complete Response 1 Non-squamous NSCLC 1 Non Small Cell Lung 1 Neoplasm Metastasis 1 Neoadjuvant Treatment for HER2-positive, ER-positive Breast Cancer 1 Metastatic Breast Cancer in the Brain 1 Lung Neoplasms 1 Locally Advanced Breast Cancer 1 HER2-positive Early Breast Cancer 1 HER2-expressing Advanced Solid Tumors 1 HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With Trastuzumab and Taxane 1 HER2+ Early or Locally Advanced Breast Cancer 1

Interventions

Carboplatin 339 Cisplatin 238 Paclitaxel 203 Radiotherapy 194 Pemetrexed 187 Docetaxel 169 Gemcitabine 157 pembrolizumab 140 Erlotinib Hydrochloride 107 Etoposide 98 Magnetic Resonance Spectroscopy 92 Bevacizumab 91 Specimen Handling 76 Nivolumab 73 Radiosurgery 71 durvalumab 69 Vinorelbine 54 osimertinib 53 Gefitinib 49 Drug Therapy 49 Irinotecan 42 atezolizumab 41 Topotecan 39 Radiation 39 Biopsy 39 Cyclophosphamide 38 Standard of Care 37 Cetuximab 35 Blood Specimen Collection 33 Taxes 32

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Lung Neoplasms × pyrotinib × Clear all

NCT06563999 2026-04-21

NUMER

Sun Yat-sen University

Phase 2 Recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡